Prehospital administration of freeze-dried (lyophilized) plasma for traumatic haemorrhagic shock

  • Mitra, Biswadev (Primary Chief Investigator (PCI))
  • Bernard, Stephen (Chief Investigator (CI))
  • Reade, Michael C. (Chief Investigator (CI))
  • Wood, Erica (Chief Investigator (CI))
  • McQuilten, Zoe (Chief Investigator (CI))
  • Gruen, Russell (Chief Investigator (CI))
  • Maegele, Marc G. (Associate Investigator (AI))

Project: Research

Project Details

Project Description

Haemorrhage is responsible for over 40% of all trauma-related deaths, with nearly half occurring in the pre-hospital setting. In-hospital resuscitation of haemorrhaging injured patients deliver large volumes of blood products, including plasma to combat clotting disorders in the setting of tissue injury and shock. Transfusion of a high ration of plamsa:red cells have been associated with improved outcomes after trauma. But there is limited availability evidence to guide pre-hospital transfusion of plasma.

This will be an open label, randomised controlled trial. In Victoria, the decision to transfuse pre-hospital red cells require approval by a clinician at the base. It is at this time that eligible patients will be randomised to receive freeze dried plasma or proceed with standard care.
Short titlePre-hospital FDP for trauma
Effective start/end date1/05/2131/12/21


  • transfusion
  • plasma
  • Trauma
  • haemorrhage
  • Emergency Medicine
  • Blood 2021

    Biswadev Mitra (Invited speaker)

    21 Sep 202123 Sep 2021

    Activity: Participating in or organising an event typesContribution to conference